KRSA
Korsana·NASDAQ
--
--(--)
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About KRSA
Korsana Biosciences, Inc.
Biotech company developing therapies for neurodegenerative diseases
Chemical and pharmaceutical
09/06/2018
04/02/2019
NASDAQ Stock Exchange
1
12-31
Common stock
203 Crescent Street, Bldgs. #3/3A/4, Suite 503, Waltham, MA 02453
Develops therapeutics for neurodegenerative diseases.
Korsana Biosciences, Inc., was incorporated in the Commonwealth of Massachusetts on September 6, 2018. Korsana Biosciences was established to reduce the burden of neurodegenerative diseases on patients and caregivers. Therapeutic Targeting, developed in collaboration with Paragon Therapeutics, is a new blood-brain barrier penetrating shuttle platform designed to achieve significantly higher drug concentrations inside the brain and overcome the limitations of early shuttle technology. Korsana is advancing a series of innovative THETA therapies for neurodegenerative diseases, starting with KRSA-028 for the treatment of Alzheimer's disease.
Company Financials
EPS
KRSA has released its 2025 Q4 earnings. EPS was reported at -0.19, versus the expected -0.38, beating expectations. The chart below visualizes how KRSA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
